Movement Alert｜BIOCYTOGEN-B Rises 5.17% in Regular Trading, Half-Year Results Briefing Imminent Coupled with Qilu Pharma Licensing Deal

Market Focus09-08

On September 8, BIOCYTOGEN-B rose 5.17% in regular trading, trading at HK$61.0/share, with turnover of approximately HK$63.43 million.

On the news front, the company is scheduled to hold its half-year results briefing on September 9, drawing heightened market attention to its business outlook. Additionally, BIOCYTOGEN-B recently announced a non-exclusive licensing agreement with Qilu Pharmaceutical for a fully human nanobody molecule derived from its RenNano platform, targeting applications in the neurology therapeutic area. Under the agreement, Qilu Pharma may leverage the licensed nanobody for further R&D exploration in innovative neurological drug development.

The company's interim results released on August 27 showed H1 revenue of RMB 941 million, up 51.6% year-on-year, while net profit attributable to shareholders surged 402.3% to RMB 241 million, marking five consecutive quarters of profitability. The preclinical segment generated RMB 723 million in revenue, up 57.9%, with innovative animal model sales reaching RMB 446 million (+62.4%) at a gross margin of 82.3%. The antibody discovery business posted RMB 218 million in revenue (+33.8%) with a gross margin of approximately 92.8%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment